Immunocore (IMCR) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vir Biotechnology (VIR) has outperformed Immunocore (IMCR) over the past year, gaining 83.8% versus a loss of 14.4%. Over five years, IMCR leads with a -23.4% price change compared with -71.6% for VIR. Vir Biotechnology is the larger company by market cap ($1.88 billion vs $1.50 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | VIR |
|---|---|---|
| Share price | $29.09 | $11.12 |
| Market cap | $1.50B | $1.88B |
| 1-day change | -1.09% | -3.47% |
| YTD return | -16.19% | +84.41% |
| 1-year return | -14.42% | +83.80% |
| 5-year return | -23.45% | -71.55% |
| EPS (TTM) | $-0.36 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $11.94 |
| 52-week low | $27.56 | $4.82 |
| Distance from 52-week high | -28.55% | -6.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.64% | +86.87% |
| Average volume | 443.48K | 1.93M |
| Shares outstanding | 51.50M | 169.22M |
| Employees | 524 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed IMCR by 98.2 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
IMCR vs VIR FAQ
Which is bigger, Immunocore or Vir Biotechnology?
Vir Biotechnology (VIR) is larger, with a market capitalization of $1.88B compared with $1.50B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or VIR?
VIR returned +83.80% over the past 12 months, compared with -14.42% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.